9,122
Participants
Start Date
December 31, 2015
Primary Completion Date
June 28, 2024
Study Completion Date
June 28, 2024
Memorial Sloan Kettering Cancer Center, New York
Roswell Park Cancer Institute, Buffalo
Thomas Jefferson University Hospital, Philadelphia
Fox Chase Cancer Center, Philadelphia
Upper Chesapeake Medical Center, Patricia D. and M. Scot Kaufman Cancer Center, Bel Air
University of Maryland, Greenebaum Cancer Center, Baltimore
UMD St. Joseph Medical Center, Towson
Duke University Medical Center, Duke Cancer Institute, Durham
Hospital Universitario Fundación Jiménez Díaz, Madrid
Hospital 12 De Octubre, Madrid
Hospital Universitario 12 Octubre Avda. de Córdoba s/n, Madrid
Centro Integral Oncológico Clara Campal, HM CIOCC (START MADRID-CIOCC), Madrid
Winship Cancer Institute - Emory University, Atlanta
University Hospital of Navarra (Pamplona), Pamplona
Orlando Health, Orlando
University of Miami, Sylvester Comprehensive Cancer Center, Miami
Boca Raton Regional Hospital, Lynn Cancer Institute, 701 NW 13th Street, Boca Raton
H. Lee Moffitt Cancer Center, Tampa
Tennessee Oncology- Sarah Cannon Research Institute, Nashville
Vanderbilt-Ingram Cancer Center, Nashville
Hospital Virgen del Rocio, Sevillia, Seville
Ohio State University Wexner Medical Center, Columbus
Indiana University Simon Cancer Center, Indianapolis
Medical College of Wisconsin, Milwaukee
Northwest Oncology and Hematology, Rolling Meadows
Washington University School of Medicine, St Louis
University of Oklahoma Health Sciences Center, Oklahoma City
The University of Texas MD Anderson Cancer Center, Houston
City of Hope, Duarte
Stanford Cancer Institute (Stanford University), Stanford
Massachusetts General Hospital, Boston
Princess Margaret Cancer Centre, Toronto
Hospital Universitario Vall d'Hebron, Barcelona
Hospital Clinico Universitario de Valencia, Valencia
University College Hospital Macmillan Cancer Centre, London
The Christie NHS Foundation Trust, Manchester
Lead Sponsor
Adaptimmune
INDUSTRY